Faculty Opinions recommendation of A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1090972.544337 ◽

2007 ◽

Author(s):

Rodolfo Testa

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Overactive Bladder Syndrome ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome

BJU International ◽

10.1111/j.1464-410x.2007.07162.x ◽

2007 ◽

Vol 100 (4) ◽

pp. 840-845 ◽

Cited By ~ 55

Author(s):

Dudley Robinson ◽

Linda Cardozo ◽

Gerben Terpstra ◽

John Bolodeoku ◽

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Overactive Bladder Syndrome ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793482011 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793480560 ◽

2013 ◽

Author(s):

Howard Goldman ◽

Alana M Murphy

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study

International Journal of Clinical Practice ◽

10.1111/j.1742-1241.2008.01898.x ◽

2008 ◽

Vol 62 (11) ◽

pp. 1675-1683 ◽

Cited By ~ 27

Author(s):

M.-S Choo ◽

J. Z. Lee ◽

J. B. Lee ◽

Y.-H. Kim ◽

H. C. Jung ◽

...

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Efficacy And Safety ◽

Double Blind ◽

Korean Patients ◽

Solifenacin Succinate

Download Full-text

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

Yearbook of Urology ◽

10.1016/j.yuro.2011.05.045 ◽

2011 ◽

Vol 2011 ◽

pp. 25-26

Author(s):

E.S. Rovner

Keyword(s):

Overactive Bladder ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Dose Ranging

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793480637 ◽

2013 ◽

Author(s):

Alexander Roosen

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Faculty of 1000 evaluation for A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020708.793480105 ◽

2013 ◽

Author(s):

Altaf Mangera

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

LUTS Lower Urinary Tract Symptoms ◽

10.1111/luts.12053 ◽

2014 ◽

Vol 7 (2) ◽

pp. 84-92 ◽

Cited By ~ 15

Author(s):

Osamu YAMAGUCHI ◽

Eiji MARUI ◽

Yasuhiko IGAWA ◽

Masayuki TAKEDA ◽

Osamu NISHIZAWA ◽

...

Keyword(s):

Overactive Bladder ◽

Japanese Patients ◽

Dose Finding ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Adrenoceptor Agonist ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Efficacy and Safety of a Fixed Combination Phytomedicine in the Treatment of the Common Cold (Acute Viral Respiratory Tract Infection): Results of a Randomised, Double Blind, Placebo Controlled, Multicentre Study

Current Medical Research and Opinion ◽

10.1185/03007999909114094 ◽

1999 ◽

Vol 15 (3) ◽

pp. 214-227 ◽

Cited By ~ 37

Author(s):

H. H. Henneicke-Von Zepelin ◽

C. Hentschel ◽

J. Schnitker ◽

R. Kohnen ◽

G. Köhler ◽

...

Keyword(s):

Tract Infection ◽

Respiratory Tract ◽

Multicentre Study ◽

Fixed Combination ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Viral Respiratory Tract Infection ◽

The Common ◽

Viral Respiratory

Download Full-text

MP33-02 PROSPECTIVE MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF LIPOSOMAL BOTULINUM TOXIN-A INSTILLATION VS. PLACEBO IN TREATMENT OF PATIENTS WITH REFRACTORY OVERACTIVE BLADDER

The Journal of Urology ◽

10.1016/j.juro.2014.02.953 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Yao-Chi Chuang ◽

Jonathan Kaufmann ◽

David Chancellor ◽

Michael Chancellor ◽

Hann-Chorng Kuo

Keyword(s):

Botulinum Toxin ◽

Overactive Bladder ◽

Botulinum Toxin A ◽

Controlled Trial ◽

Efficacy And Safety ◽

Toxin A ◽

Double Blind ◽

Double Blind Placebo

Download Full-text